From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue
作者： Robert L. Cohen , Jeff Settleman
DOI: 10.1016/J.CELL.2014.05.027
关键词: Molecular analysis 、 Biology 、 Genome 、 Tumor biopsy 、 Cancer Medicine 、 Bioinformatics 、 Genomics 、 Cancer 、 Patient stratification 、 Precision oncology
摘要: Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation personalized cancer medicine. However, genomics-based patient stratification across diverse types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including development and application novel "rationally targeted" therapies.
core.ac.uk
sci-hub.se 参考文章(29)
Genomic landscapes and clonality of de novo AML. The New England Journal of Medicine. ,vol. 369, pp. 1473- 1473 ,(2013) , 10.1056/NEJMC1308782
Ana Custodio, Jaime Feliu, Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Critical Reviews in Oncology Hematology. ,vol. 85, pp. 45- 81 ,(2013) , 10.1016/J.CRITREVONC.2012.05.001
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
Daniel Heng, Ronald Bukowski, Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Current Cancer Drug Targets. ,vol. 8, pp. 676- 682 ,(2008) , 10.2174/156800908786733450
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L. Beijersbergen, Alberto Bardelli, René Bernards, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature. ,vol. 483, pp. 100- 103 ,(2012) , 10.1038/NATURE10868
Janet E. Dancey, Philippe L. Bedard, Nicole Onetto, Thomas J. Hudson, The Genetic Basis for Cancer Treatment Decisions Cell. ,vol. 148, pp. 409- 420 ,(2012) , 10.1016/J.CELL.2012.01.014
Cassandra Willyard, 'Basket studies' will hold intricate data for cancer drug approvals Nature Medicine. ,vol. 19, pp. 655- 655 ,(2013) , 10.1038/NM0613-655
Cheryl Eifert, R. Scott Powers, From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets Nature Reviews Cancer. ,vol. 12, pp. 572- 578 ,(2012) , 10.1038/NRC3299
T Eisen, T Ahmad, K T Flaherty, M Gore, S Kaye, R Marais, I Gibbens, S Hackett, M James, L M Schuchter, K L Nathanson, C Xia, R Simantov, B Schwartz, M Poulin-Costello, P J O'Dwyer, M J Ratain, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis British Journal of Cancer. ,vol. 95, pp. 581- 586 ,(2006) , 10.1038/SJ.BJC.6603291
Renuka Iyer, Gerald Fetterly, Amit Lugade, Yasmin Thanavala, Sorafenib: a clinical and pharmacologic review. Expert Opinion on Pharmacotherapy. ,vol. 11, pp. 1943- 1955 ,(2010) , 10.1517/14656566.2010.496453